{"SPADE_N_13930": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_13930", "Peptide Name": "SrnA2 (salivaricin 10A2, natural AMPs; lantibiotic, bacteriocin, Gram-positive bacteria, prokaryotes; XXT3; XXW2; UCSS1b; XXP)", "Source": "Streptococcus salivariusSALI-10. oral cavity, human microbiota:mouth, symbiont bacteria", "Family": "Not found", "Gene": "Not found", "Sequence": "GWFTAVQLTLAGRCGRWFTGSYECTTNNVKCG", "Sequence Length": 32, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 3527.96, "PI": 8.68, "Hydrophobicity": -0.11, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Barbour A, Smith L, Oveisi M, Williams M, Huang RC, Marks C, Fine N, Sun C, Younesi F, Zargaran S, Orugunty R, Horvath TD, Haidacher SJ, Haag AM, Sabharwal A, Hinz B, Glogauer M.2023", "Reference": "Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2219392120. doi: 10.1073/pnas.2219392120.Pub-Med.", "Title": "Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome."}], "Frequent Amino Acids": "GTC", "Absent Amino Acids": "DHIMOPU", "Basic Residues": 3, "Acidic Residues": 1, "Hydrophobic Residues": 11, "Polar Residues": 20, "Positive Residues": 3, "Negative Residues": 1, "Net Charge": 2, "Comments": "Chemical modification: it is unique that T4 is phosphorylated. Residues 9 and 19 are dehydrated. Thioether rings between residues 9 and 14, between 19 and 24, and between 21 and 31.Warning: activity was tested using salivaricin 10, a mixture of peptides (AP3698-3700).Activity: active against Gram+ M. luteus ATCC10240 (MIC 0.125 ug/ml), S. pyogenes W51503011 or W80908630 (MIC 16 ug/ml), S. agalactiae W73106655 or W70407881 (MIC 16-32 ug/ml), S. pneumoniae V4122578 or W81002644 (MIC 0.5-1 ug/ml), drug-resistant E. faecalis W82000259 or W80909324 or ATCC29212 (MIC 16-32 ug/ml), E. faecium W97542221 (MIC 64 ug/ml) anti-VRE, L-rhamnosus ATCC11981 (MIC>64 ug/ml), S-mutans UA159 (MIC > 64 ug/ml), Gram- N. gonorrhoeae V3091967 (MIC 64 ug/ml), P. gingivalis ATCC33277 (MIC 32 ug/ml), and T. forsythia ATCC43037 (MIC 32 ug/ml). Primarily kill oral pathogens in a selective manner.Proinflammatory: salivaricin 10 is able to increase the levels of proinflmmatory CD63 and CD66 similar to pathogens or crude peptide preparation. The phosphorylated peptide appears to be important for this activation.", "Similar Sequences": [{"SPADE_ID": "SPADE_N_13929", "Similarity": 0.96875, "Sequence": "GWFTAVQLTLAGRCGRWFTGSFECTTNNVKCG"}, {"SPADE_ID": "SPADE_N_13931", "Similarity": 0.71875, "Sequence": "GWSTAVRLTVQGRCGWWFTHSYECTSPNVRCG"}]}}}